Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients.

Trial Profile

Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Tasadenoturev (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Acronyms D24-DIPG
  • Most Recent Events

    • 05 Dec 2017 According to a DNAtrix media release, Sonia Tejada is the principal investigator.
    • 05 Dec 2017 According to a DNAtrix media release, this study protocol was published in Neurosurgery.
    • 05 Dec 2017 According to a DNAtrix media release, first pediatric patient has been treated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top